801 related articles for article (PubMed ID: 17713976)
1. The absolute oral bioavailability and population-based pharmacokinetic modelling of a novel dipeptidylpeptidase-IV inhibitor, vildagliptin, in healthy volunteers.
He YL; Sadler BM; Sabo R; Balez S; Wang Y; Campestrini J; Laurent A; Ligueros-Saylan M; Howard D
Clin Pharmacokinet; 2007; 46(9):787-802. PubMed ID: 17713976
[TBL] [Abstract][Full Text] [Related]
2. Clinical pharmacokinetics and pharmacodynamics of vildagliptin.
He YL
Clin Pharmacokinet; 2012 Mar; 51(3):147-62. PubMed ID: 22339447
[TBL] [Abstract][Full Text] [Related]
3. The influence of hepatic impairment on the pharmacokinetics of the dipeptidyl peptidase IV (DPP-4) inhibitor vildagliptin.
He YL; Sabo R; Campestrini J; Wang Y; Ligueros-Saylan M; Lasseter KC; Dilzer SC; Howard D; Dole WP
Eur J Clin Pharmacol; 2007 Jul; 63(7):677-86. PubMed ID: 17486328
[TBL] [Abstract][Full Text] [Related]
4. Dose proportionality and the effect of food on vildagliptin, a novel dipeptidyl peptidase IV inhibitor, in healthy volunteers.
Sunkara G; Sabo R; Wang Y; He YL; Campestrini J; Rosenberg M; Howard D; Dole WP
J Clin Pharmacol; 2007 Sep; 47(9):1152-8. PubMed ID: 17656620
[TBL] [Abstract][Full Text] [Related]
5. Effect of the novel oral dipeptidyl peptidase IV inhibitor vildagliptin on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects.
He YL; Sabo R; Riviere GJ; Sunkara G; Leon S; Ligueros-Saylan M; Rosenberg M; Dole WP; Howard D
Curr Med Res Opin; 2007 May; 23(5):1131-8. PubMed ID: 17519080
[TBL] [Abstract][Full Text] [Related]
6. Vildagliptin, a novel dipeptidyl peptidase IV inhibitor, has no pharmacokinetic interactions with the antihypertensive agents amlodipine, valsartan, and ramipril in healthy subjects.
He YL; Ligueros-Saylan M; Sunkara G; Sabo R; Zhao C; Wang Y; Campestrini J; Pommier F; Dole K; Marion A; Dole WP; Howard D
J Clin Pharmacol; 2008 Jan; 48(1):85-95. PubMed ID: 17986525
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics and pharmacodynamics of vildagliptin in patients with type 2 diabetes mellitus.
He YL; Serra D; Wang Y; Campestrini J; Riviere GJ; Deacon CF; Holst JJ; Schwartz S; Nielsen JC; Ligueros-Saylan M
Clin Pharmacokinet; 2007; 46(7):577-88. PubMed ID: 17596103
[TBL] [Abstract][Full Text] [Related]
8. Absorption, metabolism, and excretion of [14C]vildagliptin, a novel dipeptidyl peptidase 4 inhibitor, in humans.
He H; Tran P; Yin H; Smith H; Batard Y; Wang L; Einolf H; Gu H; Mangold JB; Fischer V; Howard D
Drug Metab Dispos; 2009 Mar; 37(3):536-44. PubMed ID: 19074975
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of pharmacokinetic and pharmacodynamic interaction between the dipeptidyl peptidase IV inhibitor vildagliptin, glyburide and pioglitazone in patients with Type 2 diabetes.
Serra D; He YL; Bullock J; Riviere GJ; Balez S; Schwartz S; Wang Y; Ligueros-Saylan M; Jarugula V; Dole WP
Int J Clin Pharmacol Ther; 2008 Jul; 46(7):349-64. PubMed ID: 18793589
[TBL] [Abstract][Full Text] [Related]
10. Disposition of vildagliptin, a novel dipeptidyl peptidase 4 inhibitor, in rats and dogs.
He H; Tran P; Yin H; Smith H; Flood D; Kramp R; Filipeck R; Fischer V; Howard D
Drug Metab Dispos; 2009 Mar; 37(3):545-54. PubMed ID: 19074976
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetic and pharmacodynamic interaction of vildagliptin and voglibose in Japanese patients with Type 2 diabetes.
Yamaguchi M; Saji T; Mita S; Kulmatycki K; He YL; Furihata K; Sekiguchi K
Int J Clin Pharmacol Ther; 2013 Aug; 51(8):641-51. PubMed ID: 23782587
[TBL] [Abstract][Full Text] [Related]
12. Effects of meal timing relative to dosing on the pharmacokinetics and pharmacodynamics of vildagliptin in Japanese patients with Type 2 diabetes.
He YL; Ito H; Yamaguchi M; Terao S; Shimada S; Irie S; Sekiguchi K
Int J Clin Pharmacol Ther; 2012 Apr; 50(4):237-47. PubMed ID: 22456294
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of the potential for steady-state pharmacokinetic interaction between vildagliptin and simvastatin in healthy subjects.
Ayalasomayajula SP; Dole K; He YL; Ligueros-Saylan M; Wang Y; Campestrini J; Humbert H; Sunkara G
Curr Med Res Opin; 2007 Dec; 23(12):2913-20. PubMed ID: 17931461
[TBL] [Abstract][Full Text] [Related]
14. Study of the pharmacokinetic interaction of vildagliptin and metformin in patients with type 2 diabetes.
He YL; Sabo R; Picard F; Wang Y; Herron J; Ligueros-Saylan M; Dole WP
Curr Med Res Opin; 2009 May; 25(5):1265-72. PubMed ID: 19364302
[TBL] [Abstract][Full Text] [Related]
15. Mechanism-based population pharmacokinetic modelling in diabetes: vildagliptin as a tight binding inhibitor and substrate of dipeptidyl peptidase IV.
Landersdorfer CB; He YL; Jusko WJ
Br J Clin Pharmacol; 2012 Mar; 73(3):391-401. PubMed ID: 22442826
[TBL] [Abstract][Full Text] [Related]
16. Effect of food on the pharmacokinetics of a vildagliptin/metformin (50/1000 mg) fixed-dose combination tablet in healthy volunteers.
He YL; Flannery B; Campestrini J; Leon S; Zinny MA; Ligueros-Saylan M; Jarugula V
Curr Med Res Opin; 2008 Jun; 24(6):1703-9. PubMed ID: 18471347
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics and pharmacodynamics of single rising intravenous doses (0.5 mg-10 mg) and determination of absolute bioavailability of the dipeptidyl peptidase-4 inhibitor linagliptin (BI 1356) in healthy male subjects.
Retlich S; Duval V; Ring A; Staab A; Hüttner S; Jungnik A; Jaehde U; Dugi KA; Graefe-Mody U
Clin Pharmacokinet; 2010 Dec; 49(12):829-40. PubMed ID: 21053992
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics of lipoyl vildagliptin, a novel dipeptidyl peptidase IV inhibitor after oral administration in rats.
Wang X; Zhang D; Xu W; Liu H; Wang W
Xenobiotica; 2010 Oct; 40(10):707-12. PubMed ID: 20735236
[TBL] [Abstract][Full Text] [Related]
19. Retrospective and Prospective Human Intravenous and Oral Pharmacokinetic Projection of Dipeptidyl peptidase-IV Inhibitors Using Simple Allometric Principles - Case Studies of ABT-279, ABT-341, Alogliptin, Carmegliptin, Sitagliptin and Vildagliptin.
Gilibili RR; Bhamidipati RK; Mullangi R; Srinivas NR
J Pharm Pharm Sci; 2015; 18(3):434-48. PubMed ID: 26517136
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of pharmacokinetic interactions between vildagliptin and digoxin in healthy volunteers.
He YL; Sabo R; Sunkara G; Bizot MN; Riviere GJ; Leon S; Ligueros-Saylan M; Dole WP; Howard D
J Clin Pharmacol; 2007 Aug; 47(8):998-1004. PubMed ID: 17660482
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
